Gainers

• Serina Therapeutics (AMEX:SER) stock moved upwards by 73.5% to $4.72 during Thursday's pre-market session. The company's market cap stands at $29.0 million.
• Healthcare Triangle (NASDAQ:HCTI) shares moved upwards by 34.67% to $0.41. The market value of their outstanding shares is at $3.2 million.
• Ensysce Biosciences (NASDAQ:ENSC) stock rose 9.65% to $0.86. The market value of their outstanding shares is at $2.7 million.
• Check-Cap (NASDAQ:MBAI) shares increased by 9.61% to $2.28. The market value of their outstanding shares is at $12.7 million.
• Korro Bio (NASDAQ:KRRO) shares rose 8.55% to $12.69. The company's market cap stands at $110.0 million.
• aTyr Pharma (NASDAQ:ATYR) shares moved upwards by 8.27% to $0.73. The company's market cap stands at $66.0 million.

Losers

• Fractyl Health (NASDAQ:GUTS) stock decreased by 32.8% to $1.23 during Thursday's pre-market session. The company's market cap stands at $280.6 million.
• ENvue Medical (NASDAQ:FEED) shares fell 10.87% to $2.05. The market value of their outstanding shares is at $2.5 million.
• Spruce Biosciences (NASDAQ:SPRB) shares decreased by 8.42% to $75.01. The market value of their outstanding shares is at $87.6 million.
• USBC (AMEX:USBC) stock declined by 7.5% to $0.57. The market value of their outstanding shares is at $237.1 million.
• Sagimet Biosciences (NASDAQ:SGMT) stock fell 7.43% to $5.42. The company's market cap stands at $190.4 million.
• AirSculpt Technologies (NASDAQ:AIRS) stock fell 7.06% to $2.7. The market value of their outstanding shares is at $181.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.